tv.qiagenbioinformatics.com marketingbiox@qiagen.com https://tv.qiagenbioinformatics.com Watch tutorials, interviews and much more on our web based TV channel! en-us Visualplatform http://blogs.law.harvard.edu/tech/rss tv.qiagenbioinformatics.com CLC bio TV Watch tutorials, interviews and much more on our web based TV channel! clc bio tv, bioinformatics, genomics, research episodic no https://tv.qiagenbioinformatics.com/files/rv0.0/sitelogo.gif https://tv.qiagenbioinformatics.com http://tv.qiagenbioinformatics.com/photo/129173501/reliable-viral-detection-by-ngs-for <p><p>Good manufacturing practices (GMP) environments, such as biologics production facilities, require transparent, reproducible and audit-ready workflows. Here, we introduce a standardized short- or long-reads NGS-based workflow for viral detection using QIAGEN CLC Genomics Workbench Software, highlighting best practices to ensure sensitivity and specificity – and support reliable viral safety testing.</p><p></p><p>You will learn:</p><ul><li><p>To implement this new end-to-end NGS analysis workflow for viral detection using any sequencing technology</p><ul><li><p>Process raw reads to final viral detection results using reproducible and traceable analysis steps, including quality control (QC), reference selection (e.g., RVDB) and contamination control</p></li></ul></li><li><p>How this new workflow aligns with GMP</p><ul><li><p>See how CLC supports audit-ready analysis through full parameter tracking, versioned references and run documentation suitable for regulated environments</p></li></ul></li><li><p>To perform sensitive and robust viral detection</p><ul><li><p>Detect low-level viral contamination using curated databases, optimized alignment strategies and result interpretation frameworks</p></li></ul></li></ul><p></p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/129173501/reliable-viral-detection-by-ngs-for"><img src="http://tv.qiagenbioinformatics.com/64968576/129173501/f5a4456b45cb8569a68f77f1cc5fef95/standard/download-38-thumbnail.jpg" width="600" height="338"/></a></p> http://tv.qiagenbioinformatics.com/photo/129173501 Mon, 13 Jul 2026 16:17:12 GMT Reliable viral detection by NGS for GMP environments Good manufacturing practices (GMP) environments, such as biologics production facilities, require transparent, reproducible and audit-ready workflows. Here, we introduce a standardized short- or long-reads NGS-based workflow for viral detection using QIAGEN CLC Genomics Workbench Software, highlighting best practices to ensure sensitivity and specificity – and support reliable viral safety testing.You will learn:To implement this new end-to-end NGS analysis workflow for viral detection using any sequencing technologyProcess raw reads to final viral detection results using reproducible and traceable analysis steps, including quality control (QC), reference selection (e.g., RVDB) and contamination controlHow this new workflow aligns with GMPSee how CLC supports audit-ready analysis through full parameter tracking, versioned references and run documentation suitable for regulated environmentsTo perform sensitive and robust viral detectionDetect low-level viral contamination using curated databases, optimized alignment strategies and result interpretation frameworks Good manufacturing practices (GMP) environments, such as biologics production facilities, require transparent, reproducible and audit-ready workflows. Here, we introduce a standardized short- or long-reads NGS-based workflow for viral detection... tv.qiagenbioinformatics.com 23:57 <p><p>Good manufacturing practices (GMP) environments, such as biologics production facilities, require transparent, reproducible and audit-ready workflows. Here, we introduce a standardized short- or long-reads NGS-based workflow for viral detection using QIAGEN CLC Genomics Workbench Software, highlighting best practices to ensure sensitivity and specificity – and support reliable viral safety testing.</p><p></p><p>You will learn:</p><ul><li><p>To implement this new end-to-end NGS analysis workflow for viral detection using any sequencing technology</p><ul><li><p>Process raw reads to final viral detection results using reproducible and traceable analysis steps, including quality control (QC), reference selection (e.g., RVDB) and contamination control</p></li></ul></li><li><p>How this new workflow aligns with GMP</p><ul><li><p>See how CLC supports audit-ready analysis through full parameter tracking, versioned references and run documentation suitable for regulated environments</p></li></ul></li><li><p>To perform sensitive and robust viral detection</p><ul><li><p>Detect low-level viral contamination using curated databases, optimized alignment strategies and result interpretation frameworks</p></li></ul></li></ul><p></p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/129173501/reliable-viral-detection-by-ngs-for"><img src="http://tv.qiagenbioinformatics.com/64968576/129173501/f5a4456b45cb8569a68f77f1cc5fef95/standard/download-38-thumbnail.jpg" width="600" height="338"/></a></p> http://tv.qiagenbioinformatics.com/photo/124968344/ngs-for-gmp-compliance-new-1 <p><p>The updated ICH Q5A(R2) guidelines recommend next-generation sequencing (NGS) as the preferred approach for detecting adventitious agents. From cell line development and viral clearance studies to contamination tracing and product characterization, NGS-based tests outperform older assays in efficacy, sensitivity and reproducibility. This forms the basis for implementation by leading regulatory authorities, including the FDA, EMA, PMDA, and MFDS, signaling a global shift in biosafety testing.</p><p>Ensure easy compliance with these new directives by using a robust, computer systems validation (CSV)-friendly software platform that supports transparency and traceability throughout your biologics production pipeline.</p><p>You will learn:</p><ul><li><p>The impact of current guidelines, including ICH Q5A(R2), FDA 21 CFR Part 11 and European Pharmacopeia Chapter 2.6.41 on biologics production</p></li><li><p>Key requirements on data integrity, audit trails, user authentication and more, for setting up GMP environments</p></li><li><p>How QIAGEN CLC Genomics Workbench and Server support achieving GMP compliance</p></li></ul><p></p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/124968344/ngs-for-gmp-compliance-new-1"><img src="http://tv.qiagenbioinformatics.com/64968568/124968344/c78662361ff154f76cb8dedeac80598a/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/124968344 Mon, 23 Mar 2026 13:16:49 GMT NGS for GMP compliance: New guidelines, new tools The updated ICH Q5A(R2) guidelines recommend next-generation sequencing (NGS) as the preferred approach for detecting adventitious agents. From cell line development and viral clearance studies to contamination tracing and product characterization, NGS-based tests outperform older assays in efficacy, sensitivity and reproducibility. This forms the basis for implementation by leading regulatory authorities, including the FDA, EMA, PMDA, and MFDS, signaling a global shift in biosafety testing.Ensure easy compliance with these new directives by using a robust, computer systems validation (CSV)-friendly software platform that supports transparency and traceability throughout your biologics production pipeline.You will learn:The impact of current guidelines, including ICH Q5A(R2), FDA 21 CFR Part 11 and European Pharmacopeia Chapter 2.6.41 on biologics productionKey requirements on data integrity, audit trails, user authentication and more, for setting up GMP environmentsHow QIAGEN CLC Genomics Workbench and Server support achieving GMP compliance The updated ICH Q5A(R2) guidelines recommend next-generation sequencing (NGS) as the preferred approach for detecting adventitious agents. From cell line development and viral clearance studies to contamination tracing and product... tv.qiagenbioinformatics.com 29:36 <p><p>The updated ICH Q5A(R2) guidelines recommend next-generation sequencing (NGS) as the preferred approach for detecting adventitious agents. From cell line development and viral clearance studies to contamination tracing and product characterization, NGS-based tests outperform older assays in efficacy, sensitivity and reproducibility. This forms the basis for implementation by leading regulatory authorities, including the FDA, EMA, PMDA, and MFDS, signaling a global shift in biosafety testing.</p><p>Ensure easy compliance with these new directives by using a robust, computer systems validation (CSV)-friendly software platform that supports transparency and traceability throughout your biologics production pipeline.</p><p>You will learn:</p><ul><li><p>The impact of current guidelines, including ICH Q5A(R2), FDA 21 CFR Part 11 and European Pharmacopeia Chapter 2.6.41 on biologics production</p></li><li><p>Key requirements on data integrity, audit trails, user authentication and more, for setting up GMP environments</p></li><li><p>How QIAGEN CLC Genomics Workbench and Server support achieving GMP compliance</p></li></ul><p></p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/124968344/ngs-for-gmp-compliance-new-1"><img src="http://tv.qiagenbioinformatics.com/64968568/124968344/c78662361ff154f76cb8dedeac80598a/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p>